High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation

This publication has 24 references indexed in Scilit:

• Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients
  Pediatric Drugs, 2002
• Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan
  Bone Marrow Transplantation, 2001
• CMV antigenemia following bone marrow transplantation: risk factors and outcomes.
  Transplantation and Cellular Therapy, 2000
• Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation
  Blood, 2000
• Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? [see comments]
  Blood, 1994
• Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind Trial
  Annals of Internal Medicine, 1993
• Treatment of Cytomegalovirus Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow Transplants
  Annals of Internal Medicine, 1988
• Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation
  Blood, 1988
• Acyclovir for Prevention of Cytomegalovirus Infection and Disease after Allogeneic Marrow Transplantation
  New England Journal of Medicine, 1988
• Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation
  The Journal of Infectious Diseases, 1986